
The European Commission has granted marketing authorization to Revolution Medicines’ RASONQUE (daraxonrasib), marking the approval of the first broad RAS-targeted medicine for adults with metastatic pancreatic adenocarcinoma. Indicated as a once-daily oral monotherapy for patients who have undergone at least one prior systemic treatment, the drug addresses one of the most aggressive and historically difficult-to-treat malignancies in clinical oncology. Notably, the regulatory approval covers patients both with and without an identified RAS tumor mutation, expanding access to precision targeted cancer therapy across the European Union.